Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

PROSCA/BLADDR 2022 | Highlights from PROSCA/BLADDR 2022

Aristotelis Bamias • 19 Oct 2022
PROSCA/BLADDR 2022
Bladder Cancer Genitourinary Cancer Prostate Cancer

Aristotelis Bamias, MD, University of Athens, Athens, Greece, shares highlights from the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR 2022), held in Athens, Greece. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR 2022) in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Aristotelis Bamias

2:06
IMvigor130: clinical implications and next steps
Aristotelis Bamias • 18 Feb 2023
1:12
ASCO GU 2023: moving immunotherapy into the first-line setting for bladder cancer
Aristotelis Bamias • 18 Feb 2023
0:58
Unmet needs in regards to immunotherapy for bladder cancer
Aristotelis Bamias • 18 Feb 2023
2:18
Final OS results of IMvigor130: 1L atezolizumab +/- chemotherapy in metastatic urothelial carcinoma
Aristotelis Bamias • 18 Feb 2023

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals